Table 4.
Multivariate analysis of biomarkers in patients with brain metastasis from the Luminal and non-Luminal groups.
| Patients (N = 199)a |
||||
|---|---|---|---|---|
| Biomarker | Luminal group (N = 136) |
Non-Luminal group (N = 63) |
||
| OR (95% CI) | p | OR | (95% CI) | p |
| FN14 | 36.70 (3.65–368.25) | 0.002 | 3.29 (0.64–16.79) | 0.153 |
| GRP94 | 5.74 (0.87–37.66) | 0.069 | 3.23 (0.98–10.63) | 0.053 |
| FN14 + GRP94b | 7.10 (0.88–57.51) | 0.066 | 4.04 (1.19–13.65) | 0.025 |
| FN14 + GRP94 + Her2b | 5.80 (0.86–39.08) | 0.071 | 2.45 (0.73–8.22) | 0.147 |
The covariates used in this study were as follows: age, axillary lymph node involvement, Her2 status, and presence of lung metastasis. Her2 was not included as a covariate when we used the combination GRP94 + FN14 + Her2 as biomarker.
aThe number of patients (N) obtained in each group corresponds to those patients who presented all the required covariates.
bIn each case, these combinations were considered positive when at least one of the assessed molecules was positive and negative when all of them were negative.